CNS Pharmaceuticals annual return on equity
2019
2020
2021
2022
2023
2024
2025
CNS Pharmaceuticals Return on Equity (ROE) Growth & History (CNSP)
CNS Pharmaceuticals's return on equity was −296.28% for fiscal 2025.
View full CNS Pharmaceuticals company overviewCNS Pharmaceuticals annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −296.28% | +1407.11 pp |
| 2024 | 2024-12-31 | −1,703.39% | −684.61 pp |
| 2023 | 2023-12-31 | −1,018.78% | −805.10 pp |
| 2022 | 2022-12-31 | −213.68% | −69.53 pp |
| 2021 | 2021-12-31 | −144.15% | −56.37 pp |
| 2020 | 2020-12-31 | −87.78% | +22.18 pp |
| 2019 | 2019-12-31 | −109.96% | — |
CNS Pharmaceuticals quarterly return on equity
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −28.33% | −8.62 pp |
| Q1 2026 | 2026-03-31 | −214.93% | −164.77 pp |
| Q4 2025 | 2025-12-31 | −82.53% | −15.87 pp |
| Q3 2025 | 2025-09-30 | −27.94% | — |
| Q2 2025 | 2025-06-30 | −19.71% | — |
| Q1 2025 | 2025-03-31 | −50.17% | — |
| Q4 2024 | 2024-12-31 | −66.67% | — |
| Q3 2023 | 2023-09-30 | −1,267.46% | −1230.01 pp |
| Q2 2023 | 2023-06-30 | −135.25% | −106.35 pp |
| Q1 2023 | 2023-03-31 | −84.85% | −53.55 pp |
| Q4 2022 | 2022-12-31 | −65.44% | −22.80 pp |
| Q3 2022 | 2022-09-30 | −37.44% | −1.97 pp |
| Q2 2022 | 2022-06-30 | −28.90% | +3.35 pp |
| Q1 2022 | 2022-03-31 | −31.30% | −2.61 pp |
| Q4 2021 | 2021-12-31 | −42.64% | −6.04 pp |
| Q3 2021 | 2021-09-30 | −35.47% | +29.41 pp |
| Q2 2021 | 2021-06-30 | −32.25% | +19.29 pp |
| Q1 2021 | 2021-03-31 | −28.69% | +0.52 pp |
| Q4 2020 | 2020-12-31 | −36.60% | +29.90 pp |
| Q3 2020 | 2020-09-30 | −64.88% | — |
| Q2 2020 | 2020-06-30 | −51.54% | — |
| Q1 2020 | 2020-03-31 | −29.21% | — |
| Q4 2019 | 2019-12-31 | −66.50% | — |
CNS Pharmaceuticals return on equity trends
Over the last five fiscal years, CNS Pharmaceuticals's return on equity decreased from −87.78% to −296.28%, a change of −208.50 percentage points. The latest reported quarter, Q2 2026, shows −28.33%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CNS Pharmaceuticals source filings ↗